|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
SAM-COVID is a retrospective cohort study that aims to determine the impact of immunosuppressive drugs and immunoglubulins in the outcome of patients with COVID-19.
Description: Days until invasive mechanical ventilation or death, whatever happened first.Measure: Invasive ventilation or death Time: Up to 21 days
Description: Days until mechanical ventilationMeasure: Ventilation Time: Up to 21 days
Description: Days until deathMeasure: Death Time: Up to 21 days
Description: Proportion of patients developing secondary infectionsMeasure: Secondary infections Time: Up to 21 days
Description: Proportion of patients with digestive tract hemorrhageMeasure: Digestive tract hemorrhage Time: Up to 21 days
Description: Proportion of patients with imnprovement in 2 or more points in 7-point scale by WHOMeasure: Change in 7 points scale Time: Day 21
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports